Entos (now Iambic) Included in Business Insider's List of Most-Promising Healthcare Start-Ups of 2023
Press
This is some text inside of a div block.
July 19, 2023
Related announcements
Iambic to Present New Pre-Clinical NSCLC Data for IAM1363, a Selective Type II Inhibitor for HER2 Cancers, at the 2025 World Conference on Lung Cancer
